Indraratna RL, et al. - Here, researchers systematically review and meta-analyse the existing information in the literature regarding the safety of colchicine in pregnancy. It was concluded that the colchicine therapy did not significantly increase the incidence of foetal malformations or miscarriage when taken amid pregnancy. Colchicine therapy for familial Mediterranean fever (FMF) ought not to be withheld on this basis amid pregnancy.

Methods

• A systematic review was done utilizing six electronic databases, identifying all relevant studies where colchicine was administered to pregnant women, and where pregnancy-related outcomes were measured.
• Miscarriage and major foetal malformation were the primary endpoints.
• Secondary endpoints included birthweight and gestational age at birth.

Results

• In this meta-analysis, four studies were included.
• Utilization of colchicine throughout pregnancy was not related to an increased incidence of miscarriage or major foetal malformations.
• The incidence of miscarriage was significantly lower in women who took colchicine compared with those that did not.
• In women with FMF who took colchicine throughout the pregnancy, no significant difference was seen in birthweight or gestational age compared with those who did not take colchicine.
• When not limited to FMF, colchicine use was related to a significantly lower birthweight and gestational age compared with a control group including healthy women who did not take colchicine.